Health care is a vulnerability for the president entering his re-election, and his budget proposal released Monday projects billions in unspecified drug-cost savings.
(Bloomberg) –President Donald Trump is considering executive action to cut drug prices ahead of the 2020 election, officials familiar with the matter say, as he enters his re-election seeking to rebut Democratic criticism that his policies have hurt U.S. health care.
If he proceeds, Trump would force drug companies to accept lower payments from Medicare for treatments administered in doctors' offices, such as Bristol-Myers Squibb Co.'s immune-boosting Opdivo for cancer and Regeneron Pharmaceuticals Inc.'s Eylea for eye conditions. The rule would apply to certain drugs bought by the "Part B" section of Medicare, the program for the elderly and disabled.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
